976例幕上IDH野生型胶质母细胞瘤患者的长期生存者分析
该观察性回顾性单中心研究分析了2000年1月至2021年1月间976例新诊断幕上IDH野生型胶质母细胞瘤成人患者,中位总生存11.2个月(2005年后引入标准放化疗者为12.2个月),2年总生存率17.6%,5年总生存率2.2%,标准联合放化疗和MGMT启动子甲基化与2年及5年生存一致相关。
要点
- 976例幕上IDH野生型胶质母细胞瘤患者中位总生存11.2个月,5年总生存率仅2.2%。
- 标准联合放化疗和MGMT启动子甲基化与2年及5年生存一致相关。
- 21例5年生存者中18例确认为IDH野生型胶质母细胞瘤,7例(38.9%)携带可靶向基因改变。
核心结论
- IDH野生型胶质母细胞瘤患者5年总生存率极低,为2.2%。
- 更长生存的预测因素大多为治疗因素,强调在可实现时完整肿瘤治疗方案的重要性。
- 作者建议IDH野生型胶质母细胞瘤5年生存者复发时可筛查可靶向靶点。
研究设计与样本
- 观察性、回顾性、单中心研究,纳入2000年1月至2021年1月间976例新诊断幕上IDH野生型胶质母细胞瘤成人患者。
- 分析临床、影像和治疗相关因素与2年及5年生存的关联。
主要发现
- 中位总生存11.2个月(2005年后引入标准联合放化疗者为12.2个月),中位无进展生存9.4个月(2005年后为10.0个月)。
- 2年总生存率17.6%,5年总生存率2.2%;2年无进展生存率6.6%,5年无进展生存率1.1%。
- 与2年及5年生存一致相关的因素为标准联合放化疗一线肿瘤治疗和MGMT启动子甲基化。
- 与2年或5年生存显著相关的其他因素包括诊断年龄≤60岁、诊断时头痛或颅内压增高征象、强化灶接触皮层、初始影像强化灶未跨越中线、肿瘤全切除或次全切除、复发时二线肿瘤治疗。
- 21例5年生存者中18例确认为IDH野生型胶质母细胞瘤,7例(38.9%)有额外基因改变:3例FGFR突变或融合、3例PIK3CA突变、1例PTPN11突变、1例在体质性错配修复缺陷综合征背景下PMS2突变。
临床怎么用
- 作者认为更长生存的预测因素大多为治疗因素,强调在可实现时完整肿瘤治疗方案的重要性。
- 作者建议IDH野生型胶质母细胞瘤5年生存者复发时可筛查可靶向靶点。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Glioblastoma, isocitrate dehydrogenase (IDH)-wildtype is the most aggressive glioma with poor outcomes. The authors explored survival rates and factors associated with long-term survival in patients harboring a glioblastoma, IDH-wildtype. METHODS: In an observational, retrospective, single-center study, the authors examined the medical records of 976 adults newly diagnosed with supratentorial glioblastomas, IDH-wildtype between January 2000 and January 2021. They analyzed clinical-, imaging-, and treatment-related factors associated with 2-year and 5-year survival. RESULTS: The median overall survival was 11.2 months (12.2 months for patients included after 2005 and the introduction of standard combined chemoradiotherapy). The median progression-free survival was 9.4 months (10.0 months for patients included after 2005). Overall, 17.6% of patients reached a 2-year overall survival, while 2.2% of patients reached a 5-year overall survival. Furthermore, 6.6% of patients survived 2 years without progression, while 1.1% of patients survived 5 years without progression. Two factors that were consistently associated with 2-year and 5-year survival were first-line oncological treatment with standard combined chemoradiotherapy and methylated O6-methylguanine-DNA methyltransferase promoter. Other factors that were significantly associated with 2-year or 5-year survival were age at diagnosis ≤ 60 years, headaches or signs of raised intracranial pressure at diagnosis, cortical contact of contrast enhancement, no contrast enhancement crossing the midline on initial imaging, total or subtotal tumor resection, and a second line of oncological treatment at recurrence. Within 21 cases of 5-year survival, 18 were confirmed to be glioblastomas, IDH-wildtype, and 7 of the 5-year survivors (38.9%) had additional genetic alterations: 3 cases had an FGFR mutation or fusion, 3 cases had a PIK3CA mutation, 1 case had a PTPN11 mutation, and 1 case had a PMS2 mutation in the context of constitutional mismatch repair deficiency syndrome. CONCLUSIONS: Five-year overall survival in patients with glioblastoma, IDH-wildtype is extremely low. Predictors of a longer survival are mostly treatment factors, emphasizing the importance of a complete oncological treatment plan, when achievable. Glioblastoma, IDH-wildtype 5-year survivors could be screened for actionable targets in case of recurrence.
引用
- Aboubakr O, Moiraghi A, Elia A, et al. Long-term survivors in 976 supratentorial glioblastoma, IDH-wildtype patients. J Neurosurg. 2024. PMID: 39213667. doi:10.3171/2024.5.JNS24393
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。